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IKZF1 deletion (ΔIKZF1) is an important predictor of relapse in both childhood and adult B-cell precursor acute
lymphoblastic leukemia (B-ALL). Previously, we revealed that COBL is a hotspot for breakpoints in leukemia and
could promote IKZF1 deletions. Through an international collaboration, we provide a detailed genetic and clinical
picture of B-ALL with COBL rearrangements (COBL-r). Patients with B-ALL and IKZF1 deletion (n = 133) were
included. IKZF1 1-8 were associated with large alterations within chromosome 7: monosomy 7 (18%),
isochromosome 7q (10%), 7p loss (19%), and interstitial deletions (53%). The latter included COBL-r, which were
found in 12% of the IKZF1 1-8 cohort. Patients with COBL-r are mostly classified as intermediate cytogenetic risk
and frequently harbor ETV6, PAX5, CDKN2A/B deletions. Overall, 56% of breakpoints were located within COBL
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Translational Oncology Vol. 12, No. 5, 2019 IKZF1 Deletions with COBL Breakpoints Lopes et al. 727intron 5. Cryptic recombination signal sequence motifs were broadly distributed within the sequence of COBL, and
no enrichment for the breakpoint cluster region was found. In summary, a diverse spectrum of alterations
characterizes ΔIKZF1 and they also include deletion breakpoints within COBL. We confirmed that COBL is a
hotspot associated with ΔIKZF1, but these rearrangements are not driven by RAG-mediated recombination.
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B-cell precursor acute lymphoblastic leukemia (B-ALL) comprises
multiple subtypes defined by structural and numerical chromosomal
alterations. These initiating lesions include aneuploidy and chromo-
somal rearrangements, leading to expression of ectopic fusion proteins
and/or to deregulation of gene expression. During the evolution of
B-ALL, a series of secondary genomic alterations, such as DNA copy
number alterations (CNAs) and sequence mutations, usually emerges
[1]. These secondary events commonly involve deletions of genes that
encode regulators of cell-cycle (CDKN2A and CDKN2B) and B-cell
development (PAX5 and IKZF1) [2].
IKZF1 deletions occur in ~15% patients with B-ALL and are more
recurrent in the BCR-ABL1 and Philadelphia-like subgroups,
affecting more than 70% and 40% of the patients, respectively [3].
IKZF1 is located within chromosome band 7p12 and codifies the
transcription factor IKAROS. It has two main domains: a
DNA-binding zinc finger domain (encoded by exons 4-6) and a
zinc finger dimerization domain (encoded by exon 8). Some
intragenic IKZF1 deletions impair its DNA-binding domain resulting
in a dominant-negative effect (e.g. Δ4-7), while deletions of the whole
gene (Δ1-8), as well as deletions of exons 1-2 (e.g. Δ2-3) lead to the
gene haploinsufficiency. IKZF1 deletions have been associated with
dismal prognosis in both pediatric and adult B-ALL [4,5], despite the
type of deletion [6]. Interestingly, sequencing of IKZF1 breakpoints
suggested that aberrant recombination activating gene (RAG)–
mediated recombination is responsible for these deletions [7]. Due
to their clinical relevance, the identification of IKZF1 deletions has
become an essential prognostic biomarker over the last decade.
Hence, aiming to detect these deletions, we developed a rapid and
efficient polymerase chain reaction (PCR)–based method [8].
Recently, by delineating the genetic landscape of IKZF1 Δ1-8, we
identified COBL (COBL cordon-bleu WH2 repeat protein) gene as an
originating hotspot for IKZF1 deletions [9]. Here we established an
international collaboration to enable a detailed genetic and clinical
characterization of B-ALL with COBL rearrangements (COBL-r).Material and Methods
Patients
This study included 146 patients diagnosed with B-ALL and IKZF1
deletions. This patient cohort comprised two independent groups. The
first one included 133 patients with 1) IKZF1 complete deletion, Δ1-8
(n = 104); or 2) intragenic deletion of IKZF1 including exon 8, Δn-8
(n = 29). The second group referred to 13 patients already diagnosed
with IKZF1 deletions and COBL-r at collaborating centers [8–10].
Patient samples and information were obtained through the cooperativeefforts of nine centers worldwide, and the project was conducted in
accordance with the declaration of Helsinki.
Detection of IKZF1 Deletions and CNAs
IKZF1 deletions and CNAs in EBF1, JAK2, CDKN2A, CDKN2B,
PAX5, ETV6, BTG1, RB1, and the pseudoautosomal region 1-PAR1
(SHOX, CRLF2, C2F2RA, IL3RA, and P2RY8) were determined by
either multiplex ligation-dependent probe amplification (MLPA), or
single nucleotide polymorphism (SNP) array analyses. The SALSA
MLPA P335-(A3-B2) and/or SALSA MLPA P202-B1 (MRC Holland)
were used for MLPA experiments, and the data analyses were performed
using Coffalyser software. The CytoScan HDArray (Affymetrix) assessed
the occurrence of CNAs in the Brazilian (partially), British, and French
cohorts. Data were analyzed with Chromosome Analysis Suite software,
version 3.2 (Applied Biosystems), and the GRCh38/hg38 build of the
Human Genome Assembly.
Characterization of COBL Breakpoints
We developed customized MLPA assays for the screening of CNAs
within chromosome 7.The probes’ design and assay conditions have been
previously described [9]. To validate our SNP array and MLPA findings,
we performed either multiplexed long-distance PCR (M-PCR) or
long-distance inverse (LDI)-PCR. These PCR approaches allowed us to
confirm COBL-r and to determinate the breakpoints at nucleotide level.
Patient Data and Survival Analyses
For the comparison of laboratory and clinical data between patients
with or without COBL-r, we used the Pearson χ2 test. Overall
survival (OS) was defined as the time in months from the date of
diagnosis to death or to the last follow-up assessment for patients
alive. Kaplan-Meier method was used to estimate OS rates of patients
according to COBL status with differences compared by the log-rank
test. Statistical analyses were performed using R software, version
3.5.2, and P values b .05 were considered statistically significant.
Analysis of Activation-Induced Deaminase (AID) or RAG
Recognition Signal Sequences in Recombined COBL Alleles
An agnostic search for motifs located within fragments spanning
50 bp from the breakpoint junctions of COBL-r was performed using
MEME. The limit of output motifs was set to 5, and width ranged
from 2 to 15 bp. The FIMO (Find Individual Motif Occurrences)
tool was used for the analysis of WGCW and CG sequences, and the
recombination signal sequence (RSS) consensus sequence was used to
search for cryptic RSS sequences [11,12].
Results
Most of the deletions encompassing IKZF1 exon 8 were classified as
whole-gene deletions (Δ1-8: 78% vs. Δn-8: 22%). The CNAs found
Figure 1. Genetic alterations associated with IKZF1 deletions in B-ALL. (A) Patients with IKZF1 deletions spanning its exon 8 presented
four types of aberrations on chromosome 7: monosomy 7; isochromosome 7q, i(7q); 7p loss; and interstitial deletions within 7p arm.
*One cohort of 17 cases comprising only complete deletions of IKZF1 was excluded from this analysis because they would lead to a
biased estimative of CNAs' frequencies among patients with IKZF1 deletions overall. Then, patients were divided into two groups: (B)
intragenic deletions of IKZF1 spanning its exon 8 (n = 29) and (C) complete deletions of IKZF1 (n = 104). (D) The COBL rearrangements
were identified in 25 patients. Most of the deletions spanned between IKZF1 exon 1 and COBL intron 5, although they presented variable
size. (E) These patients had additional alterations, such as ETV6, PAX5, CDKN2A, and CDKN2B deletions.NA, not available. (F) Distribution
of molecular subtypes of B-ALL among patients with or without COBL-r. Legend colors illustrate alterations associated with high risk (red),
intermediate risk (blue), and good risk (green). HH, high hyperdiploidy. (G) The frequency of deletions in genes associated with B-ALL was
compared according to COBL status. PAX5, CDKN2A, CDKN2B, and ETV6 deletions were recurrently observed; however, the frequency of
these CNAs was similar for all these genes, as indicated by P values above each bar. PAR1, pseudoautosomal region 1. (H) No significant
difference was observed when comparing the overall survival of B-ALL patients with COBL-r vs. COBL wild type (P = .65).
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isochromosome 7q (6%; n = 7): 7p loss (15%; n = 17), and
interstitial deletions within 7p (66%; n = 76) (Figure 1A). Among
the Δn-8 group, most of the alterations (93%) were IKZF1 deletions
detectable by the M-PCR, i.e., Δ2-8 or Δ4-8 (Figure 1B).
Alternatively, 47% of the Δ1-8 group presented with aberrations
involving loss of the whole 7p, such as monosomy 7 (18%; n = 19),
isochromosome 7q (10%; n = 10), and 7p loss (19%; n = 20). The
remaining 55 patients (53%) harbored interstitial deletions; COBL-r
were found in 12% of the Δ1-8 cohort (Figure 1C).
We identified COBL-r in 25 B-ALL cases with IKZF1 deletions
(Figure 1D). COBL-r were detected by MLPA screening in 133
patients with B-ALL and IKZF1 deletions (n = 12) or SNP array/
NGS investigation performed at collaborating centers (n = 13), as
described in the methodology. The loss of genes located within 9p
locus — PAX5 (n = 11), CDKN2A (n = 10), and CDKN2B (n = 7)— and ETV6 deletions (n = 10) were the most recurrent additional
alterations among these patients (Figure 1E). Demographic and
laboratory data for the 25 patients with COBL-r showed they
included 17 males and 8 females who were mainly children and
adolescents (n = 21), with a median age at diagnosis of 5.5 years
(range 1-59 years) and a median white blood cell count of 7.5 × 109/l
(range 1.5-459.6 × 109/l) (Table 1). The patients were treated on
diverse therapy protocols (Table 2). Seven patients relapsed within a
median of 5.5 years (range 1.4-16.3 years), and six of them
experienced isolated disease recurrence in the bone marrow (n = 5)
or testes (n = 1). One patient relapsed at both sites: bone marrow and
central nervous system. The median follow-up was 5.1 years (range
0.3-16.3 years), and the five deaths (mainly in patients with early
relapse) occurred at a median 4.2 years (range 0.3-5.5 years)
following diagnosis. In addition, the comparison between patients
with COBL-r vs. COBL wild-type revealed that both groups presented
Table 1. Demographic and Laboratory Characteristics of B-ALL Cases with COBL Rearrangements. *
Patient Age (Years) Gender WBC (×109/l) Blasts at BM 5′ Breakpoint 3′ Breakpoint Detection Method Karyotype
P004 1 F 96.000 95% ELMO1 intron 14 Upstream COBL SNP array 46,XX,+2,t(3;16)(p21;p13),del(4)(q22),−7,
der(12)t(7;12)(q11;p13),−13,+16,−18,−19,+mar1,+mar2
P034 1 M 3.400 98% RAD50 intron 5 COBL intron 5 LDI-PCR NA
P086 1 M 5.000 95% 7pter COBL intron 7 MLPA/LDI-PCR NA
P120 1 F 459.600 80% 7p14 COBL intron 5 SNP array/M-PCR NA
P056 2 F 1.600 98% SPATA intron 1 COBL intron 5 LDI-PCR 46,XX
P122 2 M 13.400 40% 7pter COBL intron 7 MLPA NA
P145 2 F 92.000 98% TCRGC2 intron 1 COBL intron 13 SNP array 47,XX,del(7)(p11),+10,add(12)(p13),del(12)(p11.2)[4]
P022 4 F 7.500 85% 7p12 COBL intron 2-5 MLPA 46,XX
P003 5 M 10.000 95% IKZF1 intron 3 COBL intron 5 SNP array/M-PCR 46,XY
P074 5 M 16.400 78% 7p12.1 COBL intron 5 ‡ LDI-PCR NA
P079 5 F 5.700 88% 7p COBL intron 8-13 MLPA NA
P121 5 F 7.470 50% 7p12.2 COBL intron 5 SNP array/M-PCR NA
P144 5 M 31.000 NA 7p14.2 COBL intron 5 SNP array 47,XY,+X,del(16)(q13),i(17)(q10),
ider(21)(q10)dup(21)(q?)[3]/ 47,idem,add(7)(p1)[3]
P002 6 M 115.000 97% 7p12.2 COBL intron 5 SNP array/M-PCR 46,XY,del(6)(q21q25),der(12)del(12)
(p11p13)t(12;17)(p13;q11),der(17)t(12;17)
P069 10 F 204.000 89% IKZF1 intron 1 COBL intron 5 LDI-PCR NA
P146 11 M 1.500 90% SPATA intron 2 COBL intron 5 SNP array 48,XY,+X,?t(6;20)(p1;q1),?t(7;9)(p1;p2),
i(9)(q10),+12,der(21)dup(21)(q?)[9]
P068 12 M NA NA IKZF1 intron 3 COBL intron 5 RNA-seq/LDI-PCR 48,XY,+X,del(4)(q25),−7,del(9)del(9)
t(4;9)(q25;p13),+21,+mar[cp8]/
P104 13 M 1.680 84% 7p14 COBL intron 5 MLPA 46,XY,del(7)(p14),der(9;12)(q10;q10),+mar[6]
P090 15 M 4.500 83% 7p22 COBL intron 5 MLPA NA
P114 16 M 55.000 45% 7p COBL intron 2-5 MLPA NA
P143 16 M 6.200 96% COBL intron 1 † 7p12.1 SNP array 46,XY,idic(9)(p13)[1]/ 45,idem,−7[3]/
45,idem,add(2)(p25),−7[9]
P147 Adolescent M NA NA SUN3 intron 5 COBL intron 5 NGS NA
P005 21 M 2.820 90% 7pter Upstream COBL SNP array 46,XY,t(9;22)(q34;q11)
P006 38 M 3.040 67% VWC2 intron 3 Upstream COBL SNP array 46,XY
P001 59 M 58.000 75% 7p12 COBL intron 7 § SNP array 45,XY,−7,t(9;22;15)(p24;q11;q21),add(9)(p13)
BM, bone marrow; LDI-PCR, long-distance inverse PCR; M-PCR, multiplex PCR; MLPA, multiplex ligation-dependent probe amplification; NA, not available; WBC, white blood cell count.
* In this case, blast percent was estimated from peripheral blood.
† Patient had COBL rearrangement and 7p12.3::GRB10 intron 5 deletion.
‡ Patient had an inversion within COBL intron 5.
§ Patient had COBL rearrangement and monosomy 7.
Table 2. Clinical Characteristics and Outcome of B-ALL Cases with COBL Rearrangements
Patient Clinical Trial CNS Disease MRD Day 33 MRD Day 78 PR CMR Day 33 Relapse Outcome Follow-Up (Months)
P147 AALL0232_1 NA NA NA NA NA NA NA NA
P068 AALL0331/UKALLR3 No Negative Negative NA Yes BM Dead 45
P034 AIEOP-BFM ALL2000 No Negative Negative Good Yes No 1st CR 96
P022 AIEOP-BFM ALL2000 No Negative Negative Good Yes No 1st CR 79
P114 AIEOP-BFM ALL2000 No NA NA Good Yes NA Dead NA
P120 AIEOP-BFM ALL2000 No Positive Positive Poor No No Dead 4
P104 ALL IC 2009 Yes Negative Negative Good Yes No 1st CR 38
P145 UKALL2003 No Negative Negative NA Yes No 1st CR 105
P146 UKALL2003 No Negative NA NA Yes BM, CNS Dead 66
P144 UKALL97 No NA NA NA Yes No 1st CR 26
P143 UKALL97 No NA NA NA Yes No 1st CR 167
P003 CAALLF01 No Negative NA Good Yes NA 1st CR 4
P079 COALL 05-92 No NA NA NA Yes No 1st CR 161
P086 COALL 06-97 No Negative NA NA Yes Testes 2nd CR 195
P074 COALL 06-97 No Negative NA NA Yes BM 2nd CR 154
P069 COALL 07-03 No Positive NA NA No No 1st CR 123
P004 EORTC 58081 No Negative Negative Good Yes No 1st CR 49
P090 EsPhALL No Positive NA Good Yes Isolated BM Dead 56
P006 FRALLE 93 No Positive Positive Poor Yes Yes Relapse 192
P002 FRALLE BT No Positive Negative Poor Yes No 1st CR 15
P122 GBTLIALL99 No NA NA Good Yes NA Alive NA
P121 GBTLIALL99 No Negative Negative Good Yes No Alive NA
P005 GRAAPH No Positive Positive Not evaluable Yes No 1st CR 27
P056 NA No Positive NA Good Yes BM Lost follow-up 17
P001 NA No Positive NA Good Yes No SCT; alive 9
BM, bone marrow; CNS, central nervous system; CMR, complete morphological remission; MRD, minimal residual disease; NA, not available; PR, prednisone response; SCT, stem-cell transplantation;
WBC, white blood cell count. MRD-negative status was defined as b0.01% leukemic cells in bone marrow and peripheral blood.
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B-ALL cytogenetic abnormalities, TCF3-PBX1 and ETV6-RUNX1
were exclusively found in patients without or with COBL-r,
respectively (Figure 1F). Although we did not observe any significant
difference in the frequency of additional gene deletions when
comparing patients with vs. without COBL-r, it is worthy of note that
CDKN2A, ETV6, and PAX5 deletions were more frequent in
patients with COBL-r (Figure 1G). Follow-up data were available for
111 B-ALL patients with (n = 20) or without COBL-r (n = 91). The
OS of patients with COBL-r was similar to those with IKZF1
deletion only (hazard ratio, 1.278; 95% CI, 0.35-4.68; P = .646)
(Figure 1H).
The breakpoints of the COBL-r were determined at nucleotide
level in 11 of the 25 cases, and 56% of breakpoints were located
within COBL intron 5 (Figure 2B). To address the possible causes of
these breakpoints, we first performed an agnostic motif search. This
analysis identified the motif CASWGTGG (E-value = 0.87) within
all 22 breakpoint sequences of COBL-r (Figure 2A; Supplementary
Table S1). CASWGTG is similar to the heptamer of the RAG RSS,
which is composed of a heptamer (5′-CACAGTG-3′) and a nonamer
(5′-ACAAAAACC-3′) sequence, interspaced by 12 or 23 random
nucleotides associated to RAG-type rearrangements. Since the
nonamer was absent in our first analysis, we then investigated the
presence of complete motifs associated with the occurrence of
rearrangements in leukemia: cryptic RSS sequence (RAG-type
fusions), WGCW (AID-type fusions), and CG sequences. WGCW
and CG sequences were not found; however, we identified cryptic
RSS in 5 out of 22 breakpoint regions, although none of them were
spanning breakpoints within COBL (Supplementary Table S2).
Additionally, we performed a robust analysis for the identification ofTable 3. Demographic and Laboratory Data of Patients with B-ALL *
COBL Rearrangement P Value
No
n = 121
Yes
n = 25
n (%) n (%)
Gender 0.473
Male 48 (39.7) 8 (32.0)
Female 73 (60.3) 17 (68.0)
Age at diagnosis 0.701
b1 year 2 (1.7) 0 (0.0)
1-9 years 49 (41.5) 12 (48.0)
≥10 years 67 (56.8) 13 (52.0)
WBC (×109/L) 0.948
b50 85 (70.2) 16 (69.6)
≥50 36 (29.8) 7 (30.4)
NCI risk 0.797
Standard 69 (58.0) 14 (60.9)
High 50 (42.0) 9 (39.1)
CNS disease 0.741
No 96 (94.1) 23 (95.8)
Yes 6 (5.9) 1 (4.2)
Prednisone response 0.143
Good 66 (91.7) 11 (78.6)
Poor 6 (8.3) 3 (21.4)
Relapse 0.607
No 75 (70.8) 13 (65.0)
Yes 31 (29.2) 7 (35.0)
Outcome 0.604
Alive 94 (77.7) 20 (83.3)
Dead 27 (22.3) 4 (16.7)
WBC, white blood cell count; NCI, National Cancer Institute of US; CNS, central nervous system.
* Pearson χ2 calculation.cryptic RSSs within the whole sequence of COBL (Figure 2, C-D).
The results revealed a broad distribution of this motif throughout the
gene and no enrichment for the breakpoint cluster located in intron 5
of COBL.
Discussion
In this study, among the Δn-8 group, the majority of the alterations
were IKZF1 deletions which had already been detected by the
M-PCR method [8]. Since the remaining Δn-8 samples harbored
deletions restricted to IKZF1, either they had DNA fusions outside
the breakpoint cluster region of IKZF1 or M-PCR failed to detect
them. Among the Δ1-8 group, COBL-r were found in 12% of the
patients. This result revealed that COBL-r are more frequent among
Δ1-8 but rarely related to Δn-8. Although COBL-r were not detected
within the Δn-8 group for the cases included in the current proposal,
we found these deletions in patients with COBL-r from a previous
study [9]. These patients had IKZF1-COBL fusions, which involved
IKZF1 intron 1 (n = 1) or intron 3 (n = 2) and COBL intron 5.
Confirming the idea that COBL represents a genomic hotspot for
IKZF1 deletions in B-ALL [9], we identified COBL-r in 25 B-ALL
cases with IKZF1 deletions. Although either good (ETV6-RUNX1,
high hyperdiploid) or high-risk (BCR-ABL1) cytogenetic groups have
been observed in some of these patients, most of them had the
so-called “B-other” subclassification with either normal or other
abnormal (BCR-JAK2, IGH-EPOR) cytogenetic profile. In the
current genetic risk stratification, many cases with COBL-r would
then be classified as intermediate cytogenetic risk. We found that
these patients also presented other secondary abnormalities com-
monly identified in B-ALL, such as PAX5 and CDKN2A/B and
ETV6 deletions. This combination is of special interest because these
patients could benefit from the newly proposed combined risk
stratification strategies, such as IKZF1plus or the UKALL-CNA
classifiers [13–15]. Considering that patients with B-ALL share
similar laboratory and clinical characteristics regardless of COBL
involvement, IKZF1 deletions may play a major role on risk
stratification for these patients.
Regarding the breakpoints of the COBL-r, it is remarkable that
56% of them were located within COBL intron 5, although this
region represents only 16% (47,770 out of 300,587 bp) of the entire
gene. Based on this observation, we formulated two hypotheses to
explain the presence of a hotspot for breakpoints within COBL: 1) the
production of a truncated COBL protein, encoded by exons 1-5 only,
could have a role on leukemogenesis, or 2) there is a breakage
mechanism involving COBL intron 5, thus enriching this area for
gene rearrangements.
COBL protein has three Wiskott-Aldrich syndrome protein
homology 2 domains for actin binding. It shows substantial
expression in neurons and muscle cells, although levels are low in
blood [16]. COBL functions as an actin nucleator, controlling
neuronal morphology and development [17]. Considering that
COBL does not play a direct role in lymphoid development, the
enrichment of COBL-r in B-ALL is more likely to be related to
mechanisms controlling DNA breakage and promotion of genetic
fusions.
Usually, genetic rearrangements in lymphoid malignancies are
caused by either AID or the RAG complex. Therefore, we searched
for motifs located within the breakpoint junctions of COBL-r, which
could potentially provide a rational explanation for the observed
chromosomal rearrangements. RSSs are recognized by RAG enzymes
Figure 2. Identification of motifs within the breakpoint sequences. (A) An agnostic motif search using MEME identified the sequence
CASWGTGG (E-value = 0.87) among 22 breakpoint sequences. (B) The map of 19 deletion breakpoints (red triangles) within COBL
revealed a hotspot located at intron 5. Three breakpoints were detected within a downstream region of 7p12.1. The sequences highlight
two breakpoint clusters located at COBL intron 5. The mapped cryptic recombination signal sequences were not statistically significant.
The cryptic recombination signal sequences (cRSS) with a spacer of 12-bp (c) and 23-bp (d) were mapped along COBL gene. The highest
RIC scores represent cRSS (blue dots) associated with RSS functionality. The gray area highlights the COBL intron 5 and breakpoint
cluster regions.
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cryptic RSS immediately internal to the breakpoints of intragenic
deletions of IKZF17. Although the mutual motif within sequences
spanning the breakpoints was similar to the heptamer sequence, ourresults do not support the idea that aberrant RAG-mediated
recombination is the mechanism responsible for IKZF1 and COBL
codeletions.
732 IKZF1 Deletions with COBL Breakpoints Lopes et al. Translational Oncology Vol. 12, No. 5, 2019In summary, our results highlight COBL as a hotspot for
interstitial deletions within chromosome 7, especially for deletions
including the IKZF1 gene. Most of the COBL-r arose within COBL
intron 5, leading to complete deletion of IKZF1; nevertheless, we also
observed fusions between both genes. The analysis of the breakpoint
sequences revealed a common motif resembling the heptamer of
recombination signal sequence, but the analysis of the whole
consensus sequence did not provide evidence for RAG-mediated
recombination. Lastly, our study demonstrates that patients with
IKZF1 deletions are associated with worse outcome regardless of
COBL-r.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tranon.2019.02.002.
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